Oral semaglutide shows specific MACE and coronary revascularization benefits in patients with type 2 diabetesOral semaglutide shows specific heart benefits for type 2 diabetes

BackgroundWhile injectable GLP-1 receptor agonists like semaglutide have demonstrated clear cardiovascular benefits in type 2 diabetes mellitus (T2DM), the role of oral incretin-based therapies, including oral semaglutide and DPP-4 inhibitors—remains less well defined. Comprehensive evaluation of their cardiovascular efficacy is warranted.Research questionWhat are the cardiovascular outcomes associated with oral incretin-based therapies, specifically oral semaglutide and DPP-4 inhibitors, in patients with T2DM compared to placebo or standard care.MethodsWe searched electronic databases for randomized controlled trials (RCTs). Meta-analysis was conducted in R version 4.4.3 using the “meta” and “metasens” packages. Statistical analysis was performed using R software and RStudio (version 4.4.2). We calculated pooled estimates using risk ratios (RR) with 95% confidence intervals (CIs).ResultsA total of 9 studies comprising 67,679 patients were included, of which two evaluated oral semaglutide and the remaining seven assessed DPP-4 inhibitors. There was no significant reduction in all-cause mortality (RR 0.97, 95% CI 0.90–1.04, p = 0.35) or cardiovascular death (RR 0.98, 95% CI 0.91–1.05, p = 0.48). Major adverse cardiovascular events (MACE) showed a non-significant reduction overall (RR 0.95, 95% CI 0.91–1.00, p = 0.06), with oral semaglutide demonstrating a significant benefit (RR 0.86, 95% CI 0.78–0.95, p = 0.003). Non-fatal myocardial infarction (MI) (RR 0.98, 95% CI 0.88–1.09) and non-fatal stroke (RR 0.93, 95% CI 0.83–1.03) were not significantly affected. Hospitalizations due to heart failure (RR 0.98, 95% CI 0.84–1.13) and unstable angina (RR 1.00, 95% CI 0.87–1.15) remained unchanged. Coronary revascularization was slightly reduced with oral semaglutide (RR 0.76, 95% CI 0.64–0.91). Adverse events leading to discontinuation were higher with oral semaglutide (RR 1.51, 95% CI 1.15–1.98), while serious adverse events were significantly reduced (RR 0.96, 95% CI 0.94–0.99, p = 0.003). Sensitivity analyses were conducted due to significant heterogeneity in key outcomes. While omitting certain studies reduced heterogeneity, the overall results remained consistent.ConclusionOral incretin-based therapies were not associated with significant reductions in all-cause mortality, cardiovascular death, or MACE overall, though oral semaglutide showed a significant MACE benefit and reduced coronary revascularization on subgroup analysis. Non-fatal MI, fatal or non-fatal MI, non-fatal stroke, fatal or non-fatal stroke and hospitalization due to heart failure or unstable angina were unaffected, and oral semaglutide carried a higher risk of treatment discontinuation. These findings suggest no clear class-wide cardiovascular benefit of oral incretins, with signals specific to oral semaglutide warranting confirmation in dedicated trials.Systematic Review RegistrationPROSPERO CRD420251113835.